Allegro completes enrollment in lung cancer Dx trial

Allegro Diagnostics has reached a major milestone in development of its new BronchoGen molecular diagnostic test for lung cancer: Enrollment is finally complete in the Maynard, MA-company's 1,320-patient AEGIS II clinical trial. Researchers are testing how well BronchoGen works along with a bronchoscopy to detect early signs of lung cancer, compared to a bronchoscopy alone. Data from the trial is expected by mid-2013. Allegro President and CEO Michael Webb told FierceMedicalDevices earlier this summer that the company is working to raise between $15 million and $20 million in Series B financing to help complete clinical testing and fuel an early 2013 commercial launch of the BronchoGen product. Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.